CTLA-4 Mab (Beijng Immunoah Pharma Tech)

N/A

Report date: 2024/07/12 11:59:38

Base Information

Drug NameCTLA-4 Mab (Beijng Immunoah Pharma Tech)
Drug Alias Name5E3 (Beijng Immunoah Pharma Tech)CTLA-4 Mab (Beijng Immunoah Pharma Tech)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionCytotoxic T-Lymphocyte-Associated Antigen 4 modulators
TargetsCytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesBeijng Immunoah Pharma Tech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijng Immunoah Pharma Tech Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A